Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00082628 · ClinicalTrials.gov registry record · Phase 3
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 326
- Enrollment target
NCT00082628 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 326 participants.
The verdict
NCT00082628, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 326 participants
- Enrollment target
Study Summary
The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more effectively than placebo.
Interventions
- DRUG Placebo
- DRUG Serostim® 4 mg
- DRUG Serostim® 2 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2004-05-28 |
| Est. Completion | 2005-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00082628
The ClinicalTrials.gov registry entry for NCT00082628 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00082628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00082628 about?
NCT00082628 is a clinical study titled "Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients". The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more e...
What is the current status of trial NCT00082628?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 326 participants. The study started on 2004-05-28. Estimated completion is 2005-09-28.
What interventions are being tested in trial NCT00082628?
The interventions under investigation include: Placebo (DRUG), Serostim® 4 mg (DRUG), Serostim® 2 mg (DRUG).
Who is sponsoring clinical trial NCT00082628?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.